Aberrant lipid metabolism reshapes the immune landscape in bone metastasis of nasopharyngeal carcinoma
The synergy between the SPHK1 inhibitor PF543 and anti-programmed cell death protein 1 therapy amplified treatment effectiveness beyond standalone approaches. Overall, the SPHK1/S1P pathway advances NPC growth and aids in suppressing immune defense. Regulation of lipid metabolism may be a therapeutic target against BM in NPC and may improve the effectiveness of immunotherapy.
Authors
- Longmei Cai (ORCID: https://orcid.org/0000-0003-0421-464X)
- Xiaohong Peng (ORCID: https://orcid.org/0000-0001-9043-5603)
- Wenxiang Deng (ORCID: https://orcid.org/0000-0002-8391-6043)
- Xiaoyue He (ORCID: https://orcid.org/0000-0003-3582-4539)
- Yingying Yao (ORCID: https://orcid.org/0000-0003-2553-9259)
- Miao Song (ORCID: https://orcid.org/0000-0002-0483-6580)
- Yuanyuan Feng
- Yanling Lin (ORCID: https://orcid.org/0000-0003-3215-0890)
- Ziyan Zhu (ORCID: https://orcid.org/0009-0006-1223-5845)
- Hongmei Wang (ORCID: https://orcid.org/0000-0003-3269-8063)
Institutions
- Southern Medical University (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-012134
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94